Advertisement
Advertisement

XENE

XENE logo

Xenon Pharmaceuticals Inc

54.68
USD
Sponsored
+0.63
+1.17%
May 20, 16:00 UTC -4
Closed
exchange

Pre-Market

54.49

-0.19
-0.35%

Xenon Pharmaceuticals Inc Profile

About

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.

Info & Links

CEO

Ian Mortimer

Headquarters

200-3650 GILMORE WAY
BURNABY, A1 V5G 4W8, CANADA

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.xenon-pharma.com

Auditor

PricewaterhouseCoopers LLP

Share holders

70

Employees

370

Xenon Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization2

5.27B

Enterprise Value

4.72B

Enterprise Value/EBITDA(ttm)

-11.51

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

7.78

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

-216.82%

Return on Equity(ttm)

-55.81%

Return on Invested Capital(ttm)

-56.94%

Return on Assets(ttm)

-52.04%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-410.19M

Net Income Available to Common(ttm)

-383.17M

Diluted EPS(ttm)

-4.36

Share Statistics

Beta (5Y Monthly)

0.74

52-Week Change

73.97%

S&P 500 52-Week Change

27.18%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

96.67M

Dividend Yield

0.00%

Float4

79.80M

% Held by Insiders

4.07%

% Held by Institutions

95.45%

Balance Sheet

Total Cash(mrq)

1.09B

Total Cash Per Share(mrq)

11.33

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

13.42%

Quick Ratio(mrq)

13.42%

Book Value Per Share(mrq)

7.27

Cash Flow

Operating Cash Flow Per Share(ytd)

-3.52

Free Cash Flow(ytd)

-279.92M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement